bm-613

BM-613 is a novel, dual-acting small molecule therapeutic agent that functions as both a thromboxane A2 receptor (TP) antagonist and a thromboxane A2 synthase (TXA2 synthase) inhibitor[1][4]. It demonstrates strong affinity for human platelet thromboxane receptors, including both TPα and TPβ isoforms, and potently inhibits thromboxane A2-induced platelet aggregation and smooth muscle contraction[1]. BM-613 also dose-dependently reduces thromboxane A2 production by human platelets. Preclinical studies show significant antiplatelet and antithrombotic effects in animal models, suggesting potential utility in thrombotic disorders such as cardiovascular disease, atherosclerosis, and pulmonary embolism[1].